• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Prostate cancer: PSA test skipping advice creates outrage | MassDevice.com On Call

Prostate cancer: PSA test skipping advice creates outrage | MassDevice.com On Call

May 22, 2012 By MassDevice staff

MassDevice On Call

MASSDEVICE ON CALL — A nationwide urologists lobbying group largely discredited guidance from a U.S. Preventative Services Task Force recommending that physicians set aside a commonly used prostate cancer screening tool.

Known as the prostate-specific antigen test, or PSA, the tool may pose more risks than benefits, according to the panel.

"Many people have a blind faith in early detection of cancer and subsequent aggressive medical intervention whenever cancer is found," American Cancer Society chief medical officer Dr. Otis Brawley wrote in an accompanying commentary on the panel’s decision. "There is little appreciation of the harms that screening and medical interventions can cause."

The panel was generally concerned about the dangers of aggressive prostate cancer treatment in patients who are asymptomatic and whose cancer may have remained neutral without intervention.

The Large Urology Group Practice Assn. expressed "outrage" at the USPSTF’s recommendation, warning that "failing to detect cancer early will create a public health catastrophe in 5-10 years," according to a press release.

"USPSTF clearly ‘cherry-picked’ data to support what can only be viewed as a pre-conceived bias against screening," LUGPA president Dr. Deepak Kapoor said in a prepared statement. "The task force did not include any physician who treats prostate cancer, and ignored credible studies and epidemiological data demonstrating a significant survival advantage to early detection…we are not detecting more cancer; we are detecting cancer earlier and saving lives."

Early results presented at the European Assn. of Urology this month from a long-term study of prostate cancer patients support the USPSTF’s decision, suggesting that surgical prostatectomy barely increased the likelihood for survival in patients with low-risk tumors.

 Health care cost spikes have little to do with waste, study shows
A study combining health data from 4 of the U.S.’s largest insurers found that, although the number of health care services provided decreased, the cost for individual services rose, posing a challenge to those who argue that cutting down on unnecessary services can help stem the ever-increasing cost of health care.
Read more

 Wearable cancer-disrupter proves as good as chemo
Novocure’s wearable, portable NovoTTF cancer-disrupting device proves as good as chemotherapy in extending overall survival for advanced brain cancer patients, with minimal side effects and far fewer impacts to a patient’s quality of life.
 
Read more

 Lower-risk sigmoidoscopy just as good as colonoscopy in preventing colon cancer deaths
A lower-risk colon examination using a sigmoidoscope was just as good at detecting colorectal cancer and reducing mortality rates as the more commonly used colonoscopy, according to the National Institutes of Health.  
Read more

 Bariatric surgery may have positive effects on blood sugar levels
A novel, experimental form of bariatric surgery helped control blood sugar levels in rats with diabetes in a study conducted at the Toronto General Hospital Research Institute.  
Read more

Filed Under: Diagnostics, News Well, Oncology Tagged With: American Cancer Society, Clinical Trials, Large Urology Group Practice Assn., National Institutes of Health (NIH), NovoCure, On Call, Prostate, U.S. Preventive Services Task Force (USPSTF)

More recent news

  • A new way to monitor glucose: Glucotrack explains 3-year CBGM implant technology
  • Dexcom continues advances in AI for CGM, type 2 diabetes awareness
  • Tandem continues to deliver more options, benefits for those with diabetes
  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy